Turning research outcomes into innovative solutions – a word from our director
As summer is approaching, we are gearing up to launch IHI call 13 – the draft topics are already available on the IHI website and will be updated in early June following the consultations with Member States and advisory groups. Registration is now open for the IHI Call Days - a must-attend if you’re thinking of applying!
Our portfolio covers the whole spectrum of health innovation, from translational research through to healthcare implementation and manufacturing. What ties our portfolio together is transformation, the ambition to take on challenges that cannot be tackled by any organisation – or indeed sector – alone, and turn research outcomes into innovative solutions. The projects in this month’s newsletter are great examples: developing patient-centric outcome measures, identifying patient stratification biomarkers, or deploying point-of-care testing protocols are all areas where the translation of high-impact research into applicable solutions requires industry, healthcare and public bodies.
But scaling these innovations towards long-term impact is hard – to support our projects, we have the Field Manual for Scaling Innovation. The field manual provides a structured framework for developing exploitation plans, value propositions and business cases. It comes with training – make sure you sign up for the masterclass by the team that developed the manual!
Niklas Blomberg, IHI Executive Director
Our portfolio covers the whole spectrum of health innovation, from translational research through to healthcare implementation and manufacturing. What ties our portfolio together is transformation, the ambition to take on challenges that cannot be tackled by any organisation – or indeed sector – alone, and turn research outcomes into innovative solutions. The projects in this month’s newsletter are great examples: developing patient-centric outcome measures, identifying patient stratification biomarkers, or deploying point-of-care testing protocols are all areas where the translation of high-impact research into applicable solutions requires industry, healthcare and public bodies.
But scaling these innovations towards long-term impact is hard – to support our projects, we have the Field Manual for Scaling Innovation. The field manual provides a structured framework for developing exploitation plans, value propositions and business cases. It comes with training – make sure you sign up for the masterclass by the team that developed the manual!
Niklas Blomberg, IHI Executive Director
Sign up for the IHI Call Days for IHI call 13
The IHI Call Days for IHI call 13 will take place from 24 to 30 June online and will include sessions on the individual topics as well as the rules and procedures.
Join our masterclass on the exploitation of project results
Join our interactive online masterclass on 3 June and discover our Field Manual on scaling innovations emerging from public-private partnerships.
IHI Forum 2026 – save the date!
Save the date for the IHI Forum 2026, which will be held in Brussels, Belgium on 20-21 October with the theme 'translating research into long-term impact'. Registration will open shortly, so watch this space!
Find out more
How to better spot people with type 1 diabetes at risk of heart disease
IMI project SOPHIA has shed new light on factors besides weight, such as blood sugar levels, that influence the risk of someone with type 1 diabetes developing heart disease.
Behavioural interventions needed with point-of-care tests to deter over-prescription of antibiotics
Value-Dx found that point-of-care testing alone cannot reduce antibiotic prescriptions. An approach taking both the physician and patient perspective into account could work.
How to make quality of life measures in clinical trials for cancer make sense
The SISAQOL project has developed a set of tools to ensure that quality of life endpoints for clinical trials for cancer treatments are meaningful, standardised and comparable.
New project applies AI to accelerate drug discovery
LIGAND-AI hopes its outputs will cut the time and cost needed to research proteins that may be implicated in diseases but have not yet been studied in detail.